The Mark Left Behind Tracked Quality of Life Better Than the Disease Did

At week 48 of the VISIBLE trial, the researchers ran a correlation nobody usually bothers with. They compared two things against how much psoriasis was affecting people’s lives.

The first was PASI — the Psoriasis Area and Severity Index, the score that decides whether a drug gets approved, whether your insurer pays for it, and whether your dermatologist thinks you are doing well. Against quality of life it came in at r equals 0.33.

The second was a questionnaire about skin discoloration left behind after the plaques cleared. It came in at 0.75.

In a population of 205 people with skin of color, the mark left behind explained the burden of the disease more than twice as well as the disease score did.

What PASI is actually made of

PASI grades three things in each of four body regions: redness, thickness, and scale. Each is scored nought to four by eye, and each carries the same weight.

So a third of the severity of your psoriasis, by construction, is how red it looks to somebody looking at it.

You know where this goes. On richly pigmented skin, plaques are commonly violaceous or dark brown rather than red, and the engineers working on objective erythema measurement have been blunt about the instruments for years: the ones that read erythema well on fair skin do not read it well on dark skin, and the reverse. A 2009 group building a chromameter-based PASI erythema score had to first sort skin into three pigmentation categories and use a different color axis, hue difference rather than redness, before scoring became consistent across them.

That work was published seventeen years ago. PASI is still scored by eye.

This is the same defect that has already been documented in the eczema severity scores and in rosacea diagnosis. Three separate conditions, one instrument problem, and it is always the redness item.

The prevalence number, and why I do not trust it as a prevalence number

The figure that gets quoted comes from NHANES: among US adults aged 20 to 59, psoriasis prevalence was 3.6 percent in white participants, 1.9 percent in African American, 1.6 percent in Hispanic, 1.4 percent in others.

Read the method. Participants were asked whether a doctor had ever told them they had psoriasis. No dermatologist saw them. No photographs were taken — the 2009 to 2010 survey did not include them, and the authors say so in their own limitations.

So the number measures diagnosed psoriasis, and the whole argument of this section is that diagnosis is where the loss happens.

A 2026 pooled analysis across NHANES and NHIS, 53,225 people and roughly twenty years, found something that makes the point without needing a dermatologist. Spanish-speaking respondents had 0.40 times the odds of a diagnosed psoriasis compared with English speakers — after adjusting for race and ethnicity, income, education, insurance and BMI. Language, independent of everything else, cut the odds of having been told you have psoriasis by 60 percent.

Nobody thinks psoriasis avoids Spanish speakers. That is a diagnosis rate wearing a prevalence costume, and the same analysis found no change in the sociodemographic distribution across two decades.

None of which means the underlying prevalence is equal. It may well be genuinely lower in some populations; psoriasis has real genetic architecture. It means the gap between 3.6 and 1.9 contains an unknown amount of undiagnosed disease, and nobody has separated the two.

When it is found, it is bigger

The clinical picture in skin of color is not simply the same disease in a different color. Body surface involvement tends to be greater at presentation, scale tends to be thicker, and the plaques are more likely to be violaceous or dark brown. Biopsy gets used more often, because the eye is less certain.

More involvement at the point of diagnosis is exactly what you would expect if the diagnosis is arriving late, and it has a consequence beyond the plaque itself. Psoriasis is a systemic inflammatory disease with cardiovascular comorbidity attached to it. Late is not a cosmetic problem.

Then the drugs, which is the good news and I want to say it plainly

Where the biologics have been examined by racial group, they work.

The risankizumab open-label extension followed 897 patients to week 100 and reported mean PASI reductions between 94.6 percent in Asian patients and 99.3 percent in Black or African American patients, with DLQI improvements of 87 to 94 percent across groups. A pooled analysis of five ixekizumab trials, 1,825 treated patients, found rapid PASI improvement in every self-identified racial group.

Both papers are careful about their own limits, and so am I. The risankizumab analysis had 25 Black patients out of 897. Some of the ixekizumab subgroups had twelve people or fewer. These are descriptive post-hoc looks at subgroups too small to detect a difference, not evidence that no difference exists.

But nothing in them suggests these drugs underperform in darker skin, and that matters, because the practical failure in this field is not that the treatments do not work. It is that they are prescribed later, to fewer people, after a longer wait.

The trial that went looking, and what it found once it stopped measuring plaques

VISIBLE is a phase 3b trial of guselkumab run across 39 sites in the US and Canada, enrolling only participants with skin of color. Its recruitment record is a separate story and a good one.

The skin clearance was strong: mean PASI improvement of 94.9 percent in the body cohort, 94.6 percent on the scalp index in the scalp cohort, most participants clear or almost clear at week 48.

Then they asked about the pigment.

Post-inflammatory pigment alteration — the light or dark patch where a plaque used to be — was measured with a purpose-built questionnaire and tracked photographically. Mean scores started at 8.4 to 9.5, which the instrument classes as moderate impact, and fell to 1.3 to 1.9 by week 48 as the skin evened out.

And at week 48, that questionnaire correlated with overall quality of life at r equals 0.7456, against PASI’s 0.3345.

Sit with the implication. In a cohort whose psoriasis was essentially cleared, the thing still driving how much the disease affected their lives was the discoloration. Not the plaques. The shadow of the plaques.

No standard psoriasis endpoint measures that. Not PASI, not the physician’s global assessment, not body surface area. A drug can hit every regulatory target in the file and leave a person with the part that actually bothers them, and the trial will record a success — because the instrument was built to see something else.

Which changes what you should be asking for

If you have psoriasis and pigmented skin, the treatment goal that gets written down is clear skin. Ask for a second one: even skin.

They are not the same target and they do not arrive at the same time. Pigment change after inflammation can persist for months to years after the plaque has gone, and the interval between clearing and evening out is the interval nobody schedules a follow-up for.

Three things follow from that. Clearing the inflammation early is the only real prevention for the mark, because the mark is proportional to how long and how hard the skin was inflamed — which makes a delayed diagnosis expensive twice over. Daily sun protection on resolving patches matters more than it does on unaffected skin, since the pigment that is already unstable is the pigment that darkens further. And the treatment for what is left is a different purchase from the treatment for the disease, with its own evidence and its own risks.

And if a clinician tells you the psoriasis is under control while you are looking at the patches every morning in the mirror, you are not being difficult. You are noticing the same thing that trial measured — that the score and the life came apart, and the score is the one that got written in the notes.

This article is educational and is not a substitute for care from someone who can look at your skin. Anything new, changing, painful or spreading should be assessed rather than researched.